Related Experiment Video
Updated: Mar 2, 2026
08:23
Phenotypic Analysis of Rodent Malaria Parasite Asexual and Sexual Blood Stages and Mosquito Stages
Published on: May 30, 2019
12.3K
Multiple primary malignant neoplasms: A 10-year experience at a single institution from Turkey
Durmus Etiz1, Evrim Metcalfe1, Melek Akcay1
1Department of Radiation Oncology, Medical Faculty, Eskisehir Osmangazi University, 26480 Eskisehir, Turkey.
Journal of Cancer Research and Therapeutics
|May 17, 2017
Summary
Multiple primary malignant neoplasms (MPMN) are increasingly common. Metachronous MPMN (mMPMN) patients had longer overall survival (OS) than synchronous MPMN (sMPMN) patients, especially females with sMPMN.
Area of Science:
- Oncology
- Cancer Research
- Epidemiology
Background:
- Rising incidence of multiple primary malignant neoplasms (MPMN) due to improved diagnostics and increased cancer survival.
- MPMN classification into synchronous (sMPMN) and metachronous (mMPMN) based on diagnosis timing.
Purpose of the Study:
- To analyze patient characteristics and overall survival (OS) in multiple primary malignant neoplasms (MPMN).
- To compare outcomes between synchronous (sMPMN) and metachronous (mMPMN) cases.
Main Methods:
- Retrospective analysis of 122 MPMN patients from January 2004 to December 2013.
- Examination of patient demographics, primary cancer types, and overall survival (OS) data.
Main Results:
- MPMN incidence was 1.2%; 69.9% were mMPMN and 30.1% were sMPMN.
- Common first primaries: head and neck, breast, gastrointestinal. Common second primaries: gastrointestinal, lung, gynecologic.
- Median OS was 30 months for sMPMN and 91 months for mMPMN. 5-year OS was 63% for sMPMN and 80% for mMPMN.
Conclusions:
- Overall survival (OS) was significantly longer in patients with metachronous multiple primary malignant neoplasms (mMPMN).
- Female patients with synchronous multiple primary malignant neoplasms (sMPMN) also showed improved OS.
- These findings highlight survival differences between MPMN subtypes.